Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies DOI Creative Commons
Joel Fundaun, Melissa Kolski, Miguel Molina‐Álvarez

et al.

JAMA Network Open, Journal Year: 2022, Volume and Issue: 5(12), P. e2248593 - e2248593

Published: Dec. 27, 2022

Importance Peripheral neuropathies are common conditions and can result in numbness, paresthesia, motor deficits, pain. There is increasing evidence for the use of biomarkers as clinical indicators presence, severity, prognosis nerve lesions; however, biomarker identification has largely been focused on disorders central nervous system, less known about their role peripheral system. Objective To assess blood-based concentrations associated with involvement patients neuropathy compared control participants. Data Sources Ovid, MEDLINE, Embase, CINAHL were searched from inception to September 23, 2021. Study Selection Observational studies reporting blood diagnosed included. This review was preregistered PROSPERO followed Preferred Reporting Items Systematic Reviews Meta-analyses ( PRISMA ) guideline. abstracted by 1 investigator independently reviewed a second. Extraction Synthesis meta-analyzed when at least 2 reported same comparable methodology. Fixed-effects models used only included; random-effects more than Main Outcomes Measures The outcome interest concentration biomarkers. Results included 36 4414 participants, including 2113 participants 2301 13 distinct diagnoses. Diabetic most diagnosis (13 studies), Charcot-Marie-Tooth disease (6 studies) Guillain-Barre syndrome studies). Overall, 16 different evaluated. neurofilament light chain, S100B, brain-derived neurotrophic factor, neuron-specific enolase. Patients demonstrated significantly higher levels chain controls (standardized mean difference [SMD], 0.93 [95% CI, 0.82 1.05]; P < .001). no significant differences S100B (SMD, 1.10 −3.08 5.28]; = .38), factor −0.52 −2.23 1.19]; .40), or enolase −0.00 −1.99 1.98]; .10) Conclusions Relevance findings this systematic meta-analysis support measure presence neuronal injury neuropathy.

Language: Английский

Traumatic brain injury: progress and challenges in prevention, clinical care, and research DOI Creative Commons
Andrew I.R. Maas, David Menon,

Geoffrey T. Manley

et al.

The Lancet Neurology, Journal Year: 2022, Volume and Issue: 21(11), P. 1004 - 1060

Published: Sept. 29, 2022

Language: Английский

Citations

648
Management of moderate to severe traumatic brain injury: an update for the intensivist DOI
Geert Meyfroidt, Pierre Bouzat, Michaël P. Casaer

et al.

Intensive Care Medicine, Journal Year: 2022, Volume and Issue: 48(6), P. 649 - 666

Published: May 20, 2022

Language: Английский

Citations

128
Prospective Harmonization, Common Data Elements, and Sharing Strategies for Multicenter Pre-Clinical Traumatic Brain Injury Research in the Translational Outcomes Project in Neurotrauma Consortium DOI
I. Wanner, Joseph T. McCabe, J. Russell Huie

et al.

Journal of Neurotrauma, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Effective team science requires procedural harmonization for rigor and reproducibility. Multicenter studies across experimental modalities (domains) can help accelerate translation. The Translational Outcomes Project in NeuroTrauma (TOP-NT) is a pre-clinical traumatic brain injury (TBI) consortium charged with establishing validating noninvasive TBI assessment tools through science. Here, we present practical approaches of research five centers providing needed vocabulary structure to achieve centralized data organization use. This includes sharing as an essential step that enables between domains, evaluating reproducibility sites, performing multimodal analyses. As part this process, TOP-NT (1) produced library TBI-relevant standard operating procedures coordinate workflow, (2) aligned 481 clinical common elements (CDEs), (3) generated 272 new CDEs. then (4) connected diverse types validate assessments domains allow multivariable phenotyping. Lastly, (5) specified technical quality controls studies. These facilitate science, distinguish wide spectrum from variability, apply quality-controls, ease higher level uses three rat models four sites. Each site collects primary outcome measures, including magnetic resonance imaging (MRI) protocols blood biomarkers neuronal glial injury, validated by histopathology behavioral outcomes. Collected are organized using the CDEs, covering surgical, behavioral, biomarker, MRI, quantitative histopathological methods. We report curation steps suited storage Open Data Commons repository, allowing unbiased cross-site analysis. approach leads introducing level, syndromic understanding signatures. authors outline semantic structural framework suggesting strategies robust multicenter trials improve translatability assessments.

Language: Английский

Citations

2
Translational Outcomes Project in Neurotrauma (TOP-NT) Pre-Clinical Consortium Study: A Synopsis DOI
Hannah L. Radabaugh, Neil Harris,

Ina B. Wanner

et al.

Journal of Neurotrauma, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Traumatic brain injury (TBI) has long been a leading cause of death and disability, yet research failed to successfully translate findings from the pre-clinical, animal setting into clinic. One factor that contributes significantly this struggle is heterogeneity observed in clinical where patients present with injuries varying types, severities, comorbidities. Modeling highly varied population laboratory remains challenging. Given feasibility constraints, individual laboratories often focus on single types are limited an abridged set outcome measures. Furthermore, tend use different or methodologies one another, making it difficult compare studies identify which pre-clinical may be best suited for translation. The NINDS-funded Translational Outcomes Project Neurotrauma (TOP-NT) multi-site consortium designed address reproducibility, rigor, transparency development validation clinically relevant biomarkers TBI. current overview article provides detailed description infrastructure strategic approach undertaken by consortium. We outline TOP-NT strategy three goals: (1) selection cross-center biomarker tools, (2) data allow sharing reuse following findable, accessible, interoperable, reusable guidelines, (3) demonstration feasibility, conducting multi-center, trial TBI development. synthesized scientific analysis results efforts will topic future articles.

Language: Английский

Citations

2
Next-Day Serum Glial Fibrillary Acidic Protein Levels to Aid Diagnosis of Sport-Related Concussion DOI
William T. O’Brien,

James W. Hickey,

Steven Mutimer

et al.

Neurology, Journal Year: 2025, Volume and Issue: 104(5)

Published: Feb. 7, 2025

Previous studies on sport-related concussion (SRC) may have measured brain injury blood-based biomarker, glial fibrillary acidic protein (GFAP), either before or after its peak, potentially underestimating the diagnostic value. The primary aim of this study was to evaluate performance serum GFAP at 24 hours post-SRC. Secondary objectives included assessing whether timing sample collection relative an Australian football match (with without SRC) affected levels, evaluating if combining with symptoms improved discrimination SRC compared alone, and determining utility neurofilament light (NfL) levels In a prospective cohort study, adult male female players Victorian Amateur Football Association (Melbourne, Australia) had blood sampled around postinjury/postmatch. NfL were quantified using Simoa assays, area under curve (AUC) values calculated for time bins 16-24 hours, 24-32 36-52 hours. Symptom severity assessed Sport Concussion Assessment Tool 5 (SCAT). A total 151 athletes (median age 22.5 years; 85% male) 97 controls 24.3 86% median 24.5 (interquartile range [IQR] 21.7-28.0; min-max 16-51.5). Time postmatch did not affect in controls; however, higher correlated shorter post-SRC (Spearman r = -0.25, 95% CI -0.40 -0.09). Median concentrations 65.9 pg/mL (IQR 49.1-81.3) controls, SRC, 124.6 86.7-190.7) 94.5 61.6-163.9) 59.9 49.1-94.7) AUC 0.83 (95% 0.76-0.90) 0.72 0.64-0.80), respectively. Furthermore, SCAT enhanced discriminatory capability alone (AUC increased from 0.91 0.97; z 2.48, p 0.01). Serum limited value ≤0.60). following potential suspected be useful objective aid diagnosis.

Language: Английский

Citations

2
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study DOI
Isabel R. A. Retel Helmrich, Endre Czeiter,

Krisztina Amrein

et al.

The Lancet Neurology, Journal Year: 2022, Volume and Issue: 21(9), P. 792 - 802

Published: Aug. 10, 2022

Language: Английский

Citations

67
Post-acute blood biomarkers and disease progression in traumatic brain injury DOI Creative Commons
Virginia Newcombe, Nicholas J. Ashton, Jussi P. Posti

et al.

Brain, Journal Year: 2022, Volume and Issue: 145(6), P. 2064 - 2076

Published: April 4, 2022

Abstract There is substantial interest in the potential for traumatic brain injury to result progressive neurological deterioration. While blood biomarkers such as glial fibrillary acid protein (GFAP) and neurofilament light have been widely explored characterizing acute (TBI), their use chronic phase limited. Given increasing evidence that these proteins may be markers of ongoing neurodegeneration a range diseases, we examined relationship imaging changes functional outcome months years following TBI. Two-hundred three patients were recruited two separate cohorts; 6 post-injury (n = 165); >5 38; 12 whom also provided data ∼8 post-TBI). Subjects underwent biomarker sampling 199) MRI 172; including diffusion tensor imaging). Data from patient cohorts compared 59 healthy volunteers 21 non-brain trauma controls. Mean diffusivity fractional anisotropy calculated cortical grey matter, deep matter whole white matter. Accelerated ageing was at level predicted age difference defined using T1-weighted images, voxel-based annualized Jacobian determinants referenced population 652 control subjects. Serum concentrations elevated early phase. GFAP values within normal months, many showed secondary temporally distinct elevations up after injury. Biomarker elevation significantly related metrics microstructural on imaging. levels volume loss years, between 5 years. Patients who worsened functionally higher than levels. can remain TBI, show temporal profiles. These correlate closely with both contemporaneous quantitative Neurofilament predict over follow-up. If confirmed, findings suggest late time points could used identify TBI survivors are high risk damage.

Language: Английский

Citations

66
Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations DOI Creative Commons
Valentina Bonetto, Laura Pasetto, Ilaria Lisi

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Dec. 15, 2022

Background Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is associated with disorders affecting the peripheral and central nervous system. A high number of patients develop post-COVID-19 syndrome persistence a large spectrum symptoms, including neurological, beyond 4 weeks after infection. Several potential mechanisms in acute phase have been hypothesized, damage blood-brain-barrier (BBB). We tested weather markers BBB association brain injury systemic inflammation may help identifying blood signature for severity neurological complications. Methods Blood biomarkers disruption (MMP-9, GFAP), neuronal (NFL) (PPIA, IL-10, TNFα) were measured two COVID-19 patient cohorts (ICUCovid; n=79) complications (NeuroCovid; n=78), control groups free from history, healthy subjects (n=20) amyotrophic lateral sclerosis (ALS; n=51). Samples collected during first second wave pandemic Lombardy, Italy. Evaluations done at chronic phases Results are levels similar to or higher than ALS. NeuroCovid display lower cytokine storm inducer PPIA but MMP-9 ICUCovid patients. There was evidence different temporal dynamics compared IL-10 showing highest phase. On contrary, patients, dependency long-term. also found clear NFL GFAP levels, deceased levels. Discussion The overall picture points an increased risk disruption. Our observations provide hints therapeutic approaches mitigating reduce dysfunction

Language: Английский

Citations

59
Blood biomarkers for traumatic brain injury: A narrative review of current evidence DOI Creative Commons
Iftakher Hossain, Niklas Marklund, Endre Czeiter

et al.

Brain and Spine, Journal Year: 2023, Volume and Issue: 4, P. 102735 - 102735

Published: Dec. 14, 2023

A blood-based biomarker (BBBM) test could help to better stratify patients with traumatic brain injury (TBI), reduce unnecessary imaging, detect and treat secondary insults, predict outcomes, monitor treatment effects quality of care. What evidence is available for clinical applications BBBMs in TBI how advance this field? This narrative review discusses the potential core TBI. literature search PubMed, Scopus, ISI Web Knowledge focused on articles English words "traumatic injury" together "blood biomarkers", "diagnostics", "outcome prediction", "extracranial "assay method" alone-, or combination. Glial fibrillary acidic protein (GFAP) combined Ubiquitin C-terminal hydrolase-L1(UCH-L1) has received FDA clearance aid computed tomography (CT)-detection lesions mild (m) Application S100B led reduction head CT scans. GFAP may also magnetic resonance imaging (MRI) abnormalities CT-negative cases Further, UCH-L1, S100B, Neurofilament light (NF-L), total tau showed value predicting mortality unfavourable outcome. Nevertheless, biomarkers have less role outcome prediction mTBI. serve as a tool multimodality monitoring neurointensive care unit. Largescale systematic studies are required explore kinetics their use multiple groups. Assay development/cross validation should generalizability those results which implicated GFAP, NF-L most promising diagnostics

Language: Английский

Citations

27
Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis DOI Open Access
Ahmed Abdelhak, Lorenzo Barba, Michele Romoli

et al.

Journal of Neurology, Journal Year: 2023, Volume and Issue: 270(7), P. 3315 - 3328

Published: May 15, 2023

Language: Английский

Citations

25